About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com. Our organization fosters our culture based on being relentless for patients, having confidence with humility, being courageous, taking insight to action and togetherness. Success for us is defined through how we improve the lives of patients and how we achieve our objectives as ONE Team.
Our approach to developing new medicines is based on applying proprietary, drug delivery technology that improves the way drugs are dosed and released. We are currently focused on the development and potential FDA approval of our lead candidate, FT218.
Avadels FT218 is an investigational, once at bedtime, extended-release formulation of sodium oxybate intended to treat excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy. Sodium oxybate is currently the standard of care for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy. However, currently approved sodium oxybate products are immediate release formulations requiring two nightly doses - one dose at bedtime and the second dose 2.5-4 hours later, in the middle of the night.
Once at bedtime FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that once at bedtime FT218 may be clinically superior to a formulation of sodium oxybate already approved by the FDA for the same indication. In particular, once at bedtime FT218 may be safer due to ramifications associated with the dosing regimen of the currently marketed twice-nightly product. Avadels market research suggests that FT218, if approved by the FDA, has the potential to command a meaningful share of the multi-billion-dollar narcolepsy treatment market. FT218 currently has patent protection until at least mid-2037 with additional patent applications pending that could extend that date beyond 2040.
On April 27, 2020, we announced positive topline results from our pivotal phase 3 REST-ON trial of once-nightly FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. On December 16, 2020, we announced the submission of our New Drug Application (NDA) in the United States for FT218. On March 1, 2021, we announced FDA acceptance of the FT218 NDA. Review and approval of the NDA is currently in process with the FDA.
We are a small, agile, and patient-obsessed team that is growing, and we have a lot of work to do in building our best-in-class team to support the launch and commercialization of FT218, if approved, and the future expansion of our portfolio. We are seeking bright people who want to roll up their sleeves, build our company together and make an impact so we can help people living with narcolepsy.
Position Summary:
The Director, Supply Chain will lead or direct all activities tied to material movement, shipping & logistics, supply/demand planning & analysis, operations process management, and other facets found within a supply chain operations department. The Director, Supply Chain will oversee all supply and customer service related Third-Party Logistic Provider activities as well as will work with various internal departments to support developing and implementing robust processes enabling a smooth and effective supply chain. This role provides functional leadership to the day-to-day operational activities of the department, complies with supply chain policies, best industry standards, and applicable regulations, as well as works in close collaboration with the External Manufacturing, Quality Assurance and Commercial teams.
Essential Functions:
Experience and Qualifications:
Other Competencies and Behaviors:
Avadel is an Equal Opportunity Employer.
PI175538479
Our free job seeker tools include alerts for new jobs, saving your favorites, optimized job matching, and more! Just enter your email below.